Lukianova N Yu, Borikun T V, Chekhun V F
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
Exp Oncol. 2019 Sep;41(3):242-247. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13615.
To study expression of miRNA derived from tumor microenvironment in patients with breast cancer (BC) as the aspect of tumor-host interaction.
The expression levels of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2/neu) were analyzed in tissue of BC using immunohistochemical method. Relative expression levels of the miR-155, -320a, and -205 were examined in tissue and sera from BC patients using quantitative reverse transcription polymerase chain reaction.
Serum and tissue miR-155, -320a, and -205 levels in patients with BC are of low diagnostic value as such for differentiation of malignant and non-malignant breast neoplasms. Nevertheless, we established the relation of circulating and tissue miR-155, -320a, and -205 to lymph node metastases and basal breast cancer subtype.
Changes of miR-155, -320a, and -205 expression in tumor tissue and sera of BC patients provide information about major clinical-pathological characteristics of BC.
从肿瘤与宿主相互作用的角度研究乳腺癌（BC）患者肿瘤微环境来源的微小RNA（miRNA）的表达情况。
采用免疫组织化学方法分析BC组织中雌激素受体、孕激素受体、人表皮生长因子受体2（HER2/neu）的表达水平。运用定量逆转录聚合酶链反应检测BC患者组织和血清中miR-155、-320a和-205的相对表达水平。
BC患者血清和组织中的miR-155、-320a和-205水平对乳腺良恶性肿瘤的鉴别诊断价值不大。然而，我们确定了循环及组织中的miR-155、-320a和-205与淋巴结转移及基底样乳腺癌亚型之间的关系。
BC患者肿瘤组织和血清中miR-155、-320a和-205表达的变化为BC的主要临床病理特征提供了信息。
